Pevion Biotech Ag

Pevion Biotech Ltd.

Biolife Science Qld Limited

Andreas Kammer

Rinaldo Zurbriggen

Mario Amacker

Silvia Rasi

Christian Moser

Nicole Westerfeld

The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein.

Multiepitope vaccine for Her2/neu-associated cancers

The present invention relates to a novel adjuvant system that generates an efficient immune response against antigens of various origins while reducing the risk of toxic side effects attendant to the use of known adjuvants. The novel adjuvant of the present invention comprises virosomes and allows antigenic molecules to be bound to or encapsulated in a variety of delivery vehicles which are easier to prepare for virosomes.

Trans-adjuvant system

The present invention relates to virosomes comprising hemagglutinin (HA) with improved fusion activity. Preferably, the HA comprised in said virosomes was derived from influenza virus produced in a cell line. The present invention also relates to compositions and a kit comprising the virosomes according to the invention. Further, the present invention relates to uses and methods involving said virosomes, as well as to a method for preparing same.

Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof

Growing community of inventors

Zollikofen, Switzerland

Andreas Kammer